Verily launches free version of its Pre Exchange and Workbench solutions, powering precision health AI and discovery

Dallas, Texas – February 18, 2026 – Verily, a precision health AI company, today announced self-serve access to Pre, the precision health platform. This launch introduces a free Standard tier account for individual researchers to access the Exchange and Workbench solutions, significantly lowering the barrier to entry for discovering and analyzing diverse biomedical datasets within a secure research environment.

Additionally, Verily has announced the addition of novel health data sources soon to be available through Exchange, enabling researchers to advance precision health discovery. These will complement the 10 unique data collections currently available from Verily and partners including from the Michael J. Fox Foundation (MJFF), Foundation for the National Institutes of Health (FNIH), the National Institutes of Health’s All of Us Research Program.

New datasets include:

• RefinedScience: Longitudinal Acute Myeloid Leukemia (AML) dataset with over 300 venetoclax and azacitidine treated patients, provides clinical and omics data including single cell transcriptomics (CITE-seq). Includes free access to the scExploreR tool, which enables exploration and analysis of single-cell data without the need for programming.
• Segmed: Real-world longitudinal database of approximately 30 million patients and 150 million de-identified imaging exams (DICOM and whole reports) plus associated clinical data. The initial dataset available through Exchange is made up of 558 patients who underwent at least one digital breast tomosynthesis (DBT) exam, including 271 patients with biopsy-proven malignant lesions.
• Transcripta Bio: A high-resolution CRISPR interference (CRISPRi) dataset containing full-transcriptome readouts of cellular states following the knockdown of genes identified as root causes for hundreds of rare diseases. Generated via Transcripta’s Drug-Gene Atlas platform, the unique dataset allows researchers to observe the molecular consequences of disease-driving genetic perturbations to speed discovery in the rare disease space.

“Through Verily Pre Exchange, researchers can access our high-quality Acute Myeloid Leukemia data pipeline and ask far more granular questions about disease biology and treatment response,” said Grant Weller, CTO at RefinedScience. “Together with Verily, we’ve accelerated the development of this clinically refined data resource and are making it available to researchers worldwide to drive faster therapeutic breakthroughs.”

“Advanced imaging data plays a critical role in precision medicine, especially when combined with clinical and other data modalities,” said David Gascoigne, CEO at Segmed. “By partnering with Verily to bring Segmed’s real-world imaging data into the Pre Exchange ecosystem, we’re expanding responsible access to high-quality, de-identified datasets within a secure, scalable research environment, helping researchers generate insights faster and accelerate the development of more precise diagnostics and therapies.”

Researchers can now access these key Verily Pre features:

• Self-Serve Account Creation: Researchers can create a free Standard tier account in minutes using a Gmail or Google Workspace email, or any Google-linked identity.
• Instant Access to Select Data Collections: Upon agreeing to a Data Use Agreement (DUA), researchers can instantly view and analyze a growing number of data collections, including the Project Baseline Health Study – Limited and PRESCO data collections.
• Integrated Analysis Environment: Users gain access to Verily Workbench which offers collaborative research features, powerful cohorting and visualization tooling, and advanced analytics to accelerate data analysis and governance, with the ability to create up to five workspaces.

“These streamlined, self-serve solutions and growing data ecosystem realizes our vision for a unified platform that connects researchers to valuable health data that can transform their research and unlock new insights,” said Bharat Rajagopal, Chief Revenue Officer at Verily. “By expanding access to Exchange and Workbench’s secure analysis environment, we are putting valuable datasets to work while empowering researchers to accelerate scientific discovery and ultimately improve human health.”

Individual researchers can now also use their self-serve accounts to upgrade to a paid Professional license, which offers access to a broader set of features, including configuring custom applications, creating additional workspaces, and uploading their own data.

About Verily
Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is uniquely positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level. For more information about Verily please visit: verily.com.

About RefinedScience
Based in Aurora, Colorado on the Anschutz medical campus, RefinedScience is an AI-driven biotech platform that leverages highly-curated multi-modal data sets created from clinical data and primary disease tissue to generate novel insights that are used to de-risk and accelerate clinical trials, drug rescues, and new data products that advance patient care. For more information about RefinedScience please visit: www.refinedscience.com.

About Segmed
Segmed, Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 30 million patients and 150 million de-identified, standardized imaging datasets and associated clinical data through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. For more information, visit www.segmed.ai or follow us on LinkedIn @segmed-ai.

About Transcripta Bio
Transcripta Bio is an AI-driven drug discovery company using its proprietary Drug-Gene and Disease Signature Atlases to accelerate the development of new medicines. By combining high-throughput transcriptomics with advanced machine learning, Transcripta maps the effects of thousands of genetic and chemical perturbations on the entire human transcriptome. This approach enables the creation of disease signatures that guide the discovery of novel drug targets and the optimization of lead candidates to treat conditions that have extreme unmet medical need. Transcripta Bio is headquartered in Palo Alto, California. For more information, visit: www.transcriptabio.com.